Neurogene (NGNE) Non-Current Deffered Revenue (2016 - 2018)
Neurogene (NGNE) reported Non-Current Deffered Revenue of $313000.0 for Q4 2018, down 30.91% on a YoY basis from $453000.0 in Q4 2017, and down 6.01% quarter-over-quarter from $333000.0 in Q3 2018.
Neurogene (NGNE) Non-Current Deffered Revenue (2016 - 2018) Analysis & Trends
Neurogene has reported Non-Current Deffered Revenue for 3 years, with the latest figure at $313000.0 in Q4 2018.
- For the quarter ending Q4 2018, Non-Current Deffered Revenue fell 30.91% year-over-year to $313000.0; the trailing twelve-month figure through Dec 2018 stood at $313000.0 (down 30.91% YoY), and the FY2018 full-year result was $313000.0, down 30.91% from the prior year.
- Non-Current Deffered Revenue for Q4 2018 stood at $313000.0, down from $333000.0 in the prior quarter.
- The five-year high for Non-Current Deffered Revenue was $518000.0 in Q1 2017, with the low at $25000.0 in Q1 2016.
- Historically, Non-Current Deffered Revenue has averaged $311666.7 across 3 years, with a median of $355000.0 in 2018.
- Annual changes were most pronounced in 2017 — Non-Current Deffered Revenue surged 1972.0% — and 2018, when it tumbled 30.91%.
- Neurogene's Non-Current Deffered Revenue stood at $150000.0 in 2016, then surged by 202.0% to $453000.0 in 2017, then plunged by 30.91% to $313000.0 in 2018.
- The last three Non-Current Deffered Revenue figures came in at $313000.0 (Q4 2018), $333000.0 (Q3 2018), and $377000.0 (Q2 2018), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Neurogene | 216.17 Mn | 216.17 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2018 | 313,000.00 |
| Sep 30, 2018 | 333,000.00 |
| Jun 30, 2018 | 377,000.00 |
| Mar 31, 2018 | 415,000.00 |
| Dec 31, 2017 | 453,000.00 |
| Sep 30, 2017 | 476,000.00 |
| Jun 30, 2017 | 508,000.00 |
| Mar 31, 2017 | 518,000.00 |
| Dec 31, 2016 | 150,000.00 |
| Sep 30, 2016 | 116,000.00 |
| Jun 30, 2016 | 56,000.00 |
| Mar 31, 2016 | 25,000.00 |